相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2viaintegrated computational approach
Salman Ali Khan et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2021)
Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review
Betsy Ann Joseph et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2021)
Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia
Jovana Milic et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2021)
Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study
Pietro Ameri et al.
CLINICAL RESEARCH IN CARDIOLOGY (2021)
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option
Tian-Tian Yao et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Guangdi Li et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms
Bodee Nutho et al.
BIOCHEMISTRY (2020)
Cobicistat: A case of mislabelled drug-drug interaction risk?
David M. Burger et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Controversial Relationship Between Renin-Angiotensin System Inhibitors and Severity of COVID-19 Announcing a Large Multicentre Case-Control Study in Italy
Augusto Di Castelnuovo et al.
HYPERTENSION (2020)
Lack of antiviral activity of darunavir against SARS-CoV-2
Sandra De Meyer et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Reply to: Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19
Laura Ambra Nicolini et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19
Jun Chen et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study
Augusto Di Castelnuovo et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2020)
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study
Augusto Di Castelnuovo et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2020)
Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Peter W. Horby et al.
LANCET (2020)
RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies
Augusto Di Castelnuovo et al.
VASCULAR PHARMACOLOGY (2020)
Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial
Yueping Li et al.
MED (2020)
Anti-HIV drug repurposing against SARS-CoV-2
Peng Sang et al.
RSC ADVANCES (2020)
Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
Bo Ram Beck et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2020)
Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat
Md Amin Hossain et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2017)
Sensitivity Analysis in Observational Research: Introducing the E-Value
Tyler J. VanderWeele et al.
ANNALS OF INTERNAL MEDICINE (2017)
Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications
Catia Marzolini et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Coronaviruses - drug discovery and therapeutic options
Alimuddin Zumla et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS
Jordi Navarro et al.
HIV AIDS-RESEARCH AND PALLIATIVE CARE (2016)
Protease inhibitors targeting coronavirus and filovirus entry
Yanchen Zhou et al.
ANTIVIRAL RESEARCH (2015)
Methods for Constructing and Assessing Propensity Scores
Melissa M. Garrido et al.
HEALTH SERVICES RESEARCH (2014)
Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial
C. Orkin et al.
HIV MEDICINE (2013)
Protease Inhibitor-Associated QT Interval Prolongation
Kimberley Hunt et al.
ANNALS OF PHARMACOTHERAPY (2011)
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
CM Chu et al.
THORAX (2004)
Modelling clustered survival data from multicentre clinical trials
DV Glidden et al.
STATISTICS IN MEDICINE (2004)
Small molecules targeting severe acute respiratory syndrome human coronavirus
CY Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Marginal structural models and causal inference in epidemiology
JM Robins et al.
EPIDEMIOLOGY (2000)
分享论文
